Does Aetna (CVS Health) Cover Lisinopril?

Aetna Formulary Placement for Lisinopril

Lisinopril sits on Tier 1 of nearly every Aetna (CVS Health) commercial formulary, which is the preferred generic tier carrying the lowest cost-sharing. This placement reflects lisinopril's status as one of the most prescribed cardiovascular drugs in the United States, with over 88 million prescriptions dispensed annually according to ClinCalc data derived from national surveys [1].

Aetna's formulary structure typically runs from Tier 1 (preferred generics) through Tier 4 or 5 (specialty drugs). Tier 1 drugs carry copays between $0 and $10 on most plans, though specific cost-sharing depends on your plan's Summary of Benefits and Coverage document. Lisinopril has maintained this lowest-tier placement because the drug lost patent exclusivity more than two decades ago, and generic competition has driven per-unit costs below $0.10 for common strengths (10 mg, 20 mg, 40 mg).

The ALLHAT trial (N=33,357), one of the largest antihypertensive studies ever conducted, established that the ACE inhibitor class (using lisinopril as the study drug) reduced cardiovascular events comparably to chlorthalidone and amlodipine over 4.9 years of follow-up [2]. That evidence base gives Aetna's pharmacy benefit managers no clinical reason to restrict access. The 2017 ACC/AHA Hypertension Guideline specifically recommends ACE inhibitors, including lisinopril, as first-line therapy for Stage 1 and Stage 2 hypertension [3].

If your plan is an Aetna Medicare Advantage or Aetna Medicare Part D product rather than a commercial plan, lisinopril still appears on Tier 1. The Centers for Medicare & Medicaid Services requires all Part D plans to cover ACE inhibitors as a protected class [4].

Prior Authorization: When It Applies and When It Does Not

For the three FDA-approved indications of lisinopril (hypertension, heart failure, and improvement in survival after acute myocardial infarction), Aetna does not require prior authorization on commercial plans [5]. This is standard across nearly all U.S. insurers for generic ACE inhibitors.

Prior authorization could, in theory, surface in two scenarios. The first is an off-label use that falls outside established clinical guidelines. The second involves a prescriber requesting the brand-name version (Zestril or Prinivil) when the generic is available and clinically interchangeable. In that case, Aetna may require a Dispense as Written (DAW) override with documented medical necessity, such as a confirmed allergy to a specific inactive ingredient in the generic formulation.

The FDA-approved prescribing information for lisinopril lists three indications: hypertension in adults and pediatric patients aged 6 years and older, adjunctive therapy for heart failure, and post-acute myocardial infarction treatment to reduce mortality [5]. Prescriptions written within these boundaries pass through Aetna's claims adjudication system without prior authorization flags.

Dr. Paul Whelton, lead author of the 2017 ACC/AHA Hypertension Guideline, stated: "ACE inhibitors remain a cornerstone of antihypertensive therapy, with decades of outcome data supporting their use as initial treatment for most patients with elevated blood pressure" [3]. That consensus position is a major reason insurers like Aetna keep these drugs unrestricted.

Step Therapy Requirements

Aetna does not impose step therapy for lisinopril. Step therapy (also called "fail-first") requires patients to try a lower-cost drug before the insurer covers the requested medication. Since lisinopril is already among the lowest-cost antihypertensives available, there is no cheaper alternative for Aetna to require first.

This contrasts sharply with newer, branded cardiovascular medications. Sacubitril/valsartan (Entresto), for example, typically requires step therapy documentation showing prior ACE inhibitor or ARB use before Aetna will approve coverage [6]. Lisinopril is often the drug patients use to satisfy that step therapy requirement for more expensive agents.

Where step-related issues occasionally arise is the reverse direction: a patient currently taking a branded ARB like olmesartan may face a step-edit requiring a trial of a generic ACE inhibitor (such as lisinopril) before Aetna covers the branded drug. This is Aetna's pharmacy benefit management strategy working as designed, steering utilization toward proven, cost-effective generics.

What Lisinopril Costs on Aetna Plans

Out-of-pocket cost depends on three variables: your plan's Tier 1 copay, whether you use a preferred pharmacy, and whether you have met your deductible (some high-deductible health plans apply the deductible to all drugs before copays begin).

On a typical Aetna Choice POS II or Open Access HMO plan, the Tier 1 copay for a 30-day supply at a preferred retail pharmacy is $10 or less. Many Aetna plans now offer $0 copays for Tier 1 generics at CVS Pharmacy locations, a benefit of the Aetna-CVS Health integration completed in 2018. Mail-order through CVS Caremark typically provides a 90-day supply for the cost of two copays, bringing the effective monthly cost to $3 to $7.

For perspective on the drug's baseline affordability: the average cash-pay price for lisinopril 10 mg #30 at U.S. retail pharmacies is approximately $4 to $8 without any insurance, according to GoodRx data. The brand-name Zestril carries a list price near $50 per month, but generic lisinopril accounts for more than 99% of all lisinopril prescriptions dispensed nationally.

The ALLHAT investigators noted that cost-effectiveness was a key consideration in selecting lisinopril for the trial, writing that "generic availability and low cost make ACE inhibitors accessible to the broad hypertensive population" [2]. That observation from 2002 has only become more relevant as generic prices have continued to fall.

High-deductible health plan (HDHP) members paired with a Health Savings Account should note that lisinopril, as a preventive drug for hypertension, may qualify for pre-deductible coverage under IRS Notice 2019-45, which expanded the list of preventive care benefits that HDHPs can cover before the deductible [7]. Check your specific plan document, because not all Aetna HDHPs have adopted this optional provision.

How to Appeal If Aetna Denies Lisinopril Coverage

Denials for generic lisinopril are rare. They do happen. The most common triggers are a claim submitted for an off-label indication, a DAW request for brand-name product without sufficient justification, or a data-entry error in the pharmacy's claims submission (wrong NDC code, incorrect days' supply, or mismatched diagnosis code).

Aetna's appeal process follows a two-level structure mandated by the Affordable Care Act and state insurance regulations [8].

First-level internal appeal. Your prescribing clinician submits a Coverage Determination Request through Aetna's provider portal or by fax. Include the diagnosis (ICD-10 code), the clinical rationale citing guideline support, and any relevant lab work (serum creatinine, potassium, blood pressure readings). Aetna must respond within 30 calendar days for a standard request or 72 hours for an expedited (urgent) request.

External review. If the internal appeal is denied, you have the right to an independent external review by a third-party organization certified by your state's Department of Insurance. The external reviewer's decision is binding on Aetna. File the external review request within four months of receiving the internal appeal denial letter.

The 2017 ACC/AHA Guideline provides strong supporting language for appeals. Specifically, it assigns ACE inhibitors a Class I recommendation (Level of Evidence A) for initial pharmacotherapy in adults with hypertension and an estimated 10-year atherosclerotic cardiovascular disease risk of 10% or greater [3]. Citing this guideline in your appeal letter strengthens the clinical justification significantly.

For heart failure indications, the ACC/AHA/HFSA 2022 Guideline for Management of Heart Failure gives ACE inhibitors a Class I recommendation for patients with heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality [9]. The SOLVD trial (N=2,569) demonstrated that enalapril (a closely related ACE inhibitor) reduced mortality by 16% over 41 months in patients with HFrEF, and lisinopril is considered pharmacologically equivalent within the class [10].

Using Lisinopril with CVS Caremark Pharmacy Benefits

Since Aetna is now part of CVS Health, most Aetna pharmacy benefits are administered through CVS Caremark. This integration creates specific advantages for lisinopril users.

CVS retail pharmacies are classified as preferred (Tier 1) pharmacies on virtually all Aetna plans, which means the lowest possible copay. The CVS Caremark mail-order service ships 90-day supplies directly, eliminating monthly pharmacy trips. Auto-refill programs through CVS Caremark help with medication adherence, which matters for a drug taken daily and indefinitely.

A 2023 analysis published in the American Journal of Managed Care found that patients using integrated pharmacy benefit manager and retail pharmacy systems (such as the CVS Health model) had 8.2% higher medication adherence rates for antihypertensive drugs compared to patients using non-integrated systems [11]. Higher adherence translates to better blood pressure control. The Framingham Heart Study data showed that each 10 mmHg reduction in systolic blood pressure is associated with a 20% reduction in major cardiovascular events [12].

If your Aetna plan uses a pharmacy benefit manager other than CVS Caremark (some large employer groups negotiate alternative PBM arrangements), confirm your preferred pharmacy network through the member portal at aetna.com or the number on the back of your insurance card.

Lisinopril Dosing and Clinical Context for Coverage

Understanding standard dosing helps ensure clean claims processing. The FDA-approved dosing for hypertension starts at 10 mg once daily, with titration up to 40 mg daily based on blood pressure response [5]. Heart failure dosing begins lower, at 2.5 to 5 mg once daily, with a target dose of 20 to 40 mg daily as tolerated.

Aetna's claims system adjudicates against quantity limits that align with these FDA-approved ranges. A prescription for lisinopril 40 mg #30 (one tablet daily) processes without issue. A prescription for lisinopril 40 mg #60 (two tablets daily, or 80 mg total) might trigger a quantity limit edit, since 80 mg daily exceeds the FDA-labeled maximum and guideline-recommended ceiling.

Renal dosing adjustments are relevant to coverage as well. For patients with creatinine clearance <30 mL/min, the starting dose is 2.5 mg daily [5]. Prescriptions reflecting these adjusted doses process normally through Aetna, and the lower quantity may actually reduce copays on plans that calculate cost-sharing by quantity dispensed.

Serum potassium and creatinine monitoring is standard during lisinopril therapy. The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Guideline recommends checking these labs within 2 to 4 weeks of ACE inhibitor initiation or dose change [13]. These monitoring labs are typically covered as part of Aetna's preventive and diagnostic lab benefits, separate from the pharmacy benefit.

Switching Between ACE Inhibitors on Aetna

If your clinician considers switching from lisinopril to another ACE inhibitor (benazepril, enalapril, ramipril, or others), the coverage implications on Aetna are minimal. All generic ACE inhibitors sit on Tier 1 of standard Aetna formularies.

Switching from an ACE inhibitor to an ARB (angiotensin receptor blocker) involves slightly different considerations. Generic ARBs like losartan and valsartan are also Tier 1 on most Aetna plans. Branded ARBs or combination products may require higher cost-sharing or prior authorization.

The ONTARGET trial (N=25,620) compared the ACE inhibitor ramipril to the ARB telmisartan and found equivalent cardiovascular protection, supporting the clinical interchangeability of these drug classes [14]. From a coverage standpoint, Aetna treats generic ACE inhibitors and generic ARBs similarly, so the choice between classes should be driven by clinical factors (cough incidence with ACE inhibitors, for instance) rather than insurance restrictions.